Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.831 GBX | -3.37% | -7.98% | -33.36% |
May. 23 | Windward wins deal; Kodal progresses at Bougouni | AN |
May. 23 | Roquefort Therapeutics plc Announces Executive and Board Changes | CI |
Business Summary
Number of employees: 10
Sales per Business
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biotechnology
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Sales per region
GBP in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United Kingdom, Europe and Australia
100.0
%
| 0 | nan % | 0 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Ajan Reginald
CEO | Chief Executive Officer | 52 | 22-09-15 |
Chairman | 51 | 20-08-16 | |
Armand Keating
CTO | Chief Tech/Sci/R&D Officer | - | 22-09-15 |
Martin Evans
BRD | Director/Board Member | 83 | 22-09-15 |
Graham Robertson
PRN | Corporate Officer/Principal | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jean Duvall
BRD | Director/Board Member | 63 | 22-04-04 |
Darrin Disley
BRD | Director/Board Member | 57 | 22-09-15 |
Chairman | 51 | 20-08-16 | |
Martin Evans
BRD | Director/Board Member | 83 | 22-09-15 |
Ajan Reginald
CEO | Chief Executive Officer | 52 | 22-09-15 |
Simon Sinclair
BRD | Director/Board Member | 52 | 22-04-19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 129,149,998 | 51,144,652 ( 39.60 %) | 0 | 39.60 % |
Company contact information
Roquefort Therapeutics Plc
Eccleston Yards 25 Eccleston Place
SW1W 9NF, London
+44 20 3918 8633
http://www.roquefortplc.comSector
1st Jan change | Capi. | |
---|---|---|
-31.03% | 8.22M | |
-4.90% | 115B | |
+10.08% | 101B | |
+11.67% | 67.41B | |
+24.65% | 66.1B | |
+14.52% | 44.58B | |
+14.85% | 43.37B | |
+19.66% | 35.13B | |
+9.42% | 26.31B | |
-2.41% | 22.77B |
- Stock Market
- Equities
- ROQ Stock
- Company Roquefort Therapeutics plc